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†
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic 
medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and 
alteplase suggest that tenecteplase is at least as efficacious as alteplase with regards to neurologic 
improvement. When given at 0.25 milligrams per kilogram (mg/kg), tenecteplase may have less 
bleeding complications than alteplase as well. This narrative review evaluates the literature and 
addresses the practical issues with regards to the use of tenecteplase versus alteplase for acute 
ischemic stroke, and it recommends that physicians consider tenecteplase rather than alteplase for 
thrombolysis of acute ischemic stroke. [West J Emerg Med. 2020;21(2)199-202.]
INTRODUCTION
Alteplase is currently the only FDA-approved medication 
for acute stroke. While alteplase has been shown to provide 
benefit to some patients who present with symptoms of 
acute stroke within 4.5 hours,1 its administration increases 
the patient’s risk of intracranial hemorrhage.2 Moreover, the 
results of some recent studies have brought up some other 
concerns about alteplase. One such example was the PRISMS 
trial.3 This study was terminated before reaching its enrollment 
goal, and was thus not definitive. However, it found that 
treatment with alteplase did not result in improved neurologic 
outcomes at 90 days as compared to aspirin for minor strokes.3 
Additionally, a small study by Wee et al found no benefit to 
administering alteplase to patients undergoing endovascular 
thrombectomy for acute stroke due to large vessel occlusion as 
compared to thrombectomy alone.4
While not FDA-approved for acute stroke, tenecteplase 
has theoretical advantages over alteplase as it has greater 
fibrin specificity and has a longer half-life than alteplase.5 It is 
the preferred thrombolytic agent for ST-elevation myocardial 
infarction in the United States.6    
Several recent studies have compared tenecteplase and 
alteplase with regards to their efficacy for the treatment of 
acute ischemic stroke. The purpose of this article is to review 
those studies as well as other practical matters with regards 
to the use of tenecteplase and alteplase. Based on these data, 
we make recommendations about the use of intravenous (IV) 
thrombolytic agents in acute ischemic stroke.
DISCUSSION
In comparing tenecteplase and alteplase for acute 
ischemic stroke, there are several issues to consider: Which 
medication is more effective with regards to neurologic 
improvement after an acute ischemic stroke? Which 
medication has less adverse effects? Which medication is 
easier to administer? Which medication costs less? Each of 
these issues will be addressed below.
Neurologic improvement after stroke
The results of five randomized controlled trials have been 
published that compare alteplase and tenecteplase for acute 
ischemic stroke.7-11 The first was by Haley et al, published 
in 2010,7 and it randomized patients with suspected acute 
ischemic stroke within 3 hours to tenecteplase 0.1 milligrams 
per kilogram (mg/kg), tenecteplase 0.25 mg/kg, tenecteplase 
0.4 mg/kg, or standard dose alteplase (0.9 mg/kg). Patients in 
the tenecteplase 0.4 mg/kg group had the lowest rate of good 
neurologic outcomes at three months (defined as modified 
Rankin scale score of 0 or 1). There were no statistically 
significant differences among the other groups, but there was 
a trend towards higher percentages of patients having good 
neurologic outcomes in the tenecteplase 0.1 mg/kg and 0.25 
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mg/kg groups as compared to the alteplase group: tenecteplase 
0.1 mg/kg 45.2%, tenecteplase 0.25 mg/kg 48.4%, and 
alteplase 41.9%
In 2012, Parsons et al published a study that randomized 
patients with suspected acute ischemic stroke with symptoms 
for 6 hours or less to tenecteplase 0.1 mg/kg, tenecteplase 
0.25 mg/kg, or standard dose alteplase. A total of 25 patients 
were enrolled in each group. Those receiving tenecteplase had 
greater reperfusion on imaging studies and superior clinical 
neurologic outcomes at 24 hours. Those receiving tenecteplase 
0.25 mg/kg had superior outcomes compared to those 
receiving alteplase for all efficacy outcomes, including serious 
disability at 90 days.8
Subsequently, in 2015, Huang et al published the results 
from a randomized trial that compared tenecteplase 0.25 mg/
kg to alteplase for patients with suspected acute ischemic 
stroke within 4.5 hours of symptom onset. A total of 104 
patients were enrolled, with 52 assigned to each group.  
There was no difference between groups with regards to the 
primary outcome of “percentage penumbra salvaged”, 68% 
in each group. There were also no statistically significant 
differences in secondary outcomes between groups, but for 
the tenecteplase group, there were trends towards more early 
neurologic improvement at 24 hours (40% vs 24%) and a 
higher percentage of good neurologic outcome at 90 days 
(28% vs 20%).9 
In 2017, Logallo et al published the results from a block-
randomized study comparing tenecteplase 0.4 mg/kg and 
standard dose alteplase for patients with suspected acute 
ischemic stroke with 4.5 hours or less of symptoms or within 
4.5 hours of awakening with symptoms. A total of 549 patients 
were randomized to the tenecteplase group and 551 were 
randomized to the alteplase group. There was no difference 
between groups in the primary outcome of good neurologic 
outcome at 90 days (64% tenecteplase vs 63% alteplase).10
Lastly, and perhaps of most interest, in 2018, Campbell 
et al published the results of a study comparing tenecteplase 
0.25 mg/kg to standard dose alteplase for patients with 
symptoms of acute ischemic stroke for less than 4.5 hours 
prior to thrombectomy. There were 101 patients in each group. 
There was a statistically significant difference between groups 
with regards to the primary outcome of reperfusion of greater 
than 50% of the involved ischemic territory or an absence of 
retrievable thrombus at the time of the initial angiographic 
assessment. This primary outcome was found in 22% of 
patients in the tenecteplase group as compared to 10% of those 
with alteplase. Patients in the tenecteplase also had superior 
functional neurologic outcomes at 90 days as compared to the 
alteplase group.11       
Four meta-analyses have been done using the clinical 
trials described above.12-15 All of these meta-analyses 
reported no statistically significant differences with regards 
to neurologic recovery, and none of the meta-analyses found 
a difference between tenecteplase and alteplase with regards 
to mortality. However, the meta-analyses by Thelengana 
and Kheiri reported significantly improved early neurologic 
improvement with tenecteplase (relative risk 1.56 confidence 
interval [CI], 1.00-2.43; p=0.05),13-14 and the meta-analysis by 
Kheiri reported significantly greater complete recanalization 
(odds ratio [OR] 2.01; 95% CI, 1.04-3.87; p=0.04).14 
In summary, five randomized controlled trials have found 
tenecteplase to be at least as effective or more effective than 
alteplase for neurologic improvement after acute ischemic 
stroke. Using the results of those five randomized controlled 
trials, four separate meta-analyses have been performed, 
and none of those concluded that alteplase is superior to 
tenecteplase.  
Adverse effects 
All of the above clinical trials and meta-analyses 
measured the rates of symptomatic and total intracerebral 
hemorrhage.7-15 Neither of the most recent meta-analyses 
found a statistically significant difference in the rates 
of intracerebral hemorrhage between tenecteplase and 
alteplase,14-15 but there were trends toward less intracerebral 
hemorrhage with tenecteplase (OR; 0.81 95% CI, 0.56-1.17; 
p=0.26).14 Notably, this value was calculated using all doses 
of tenecteplase grouped together while there is evidence that 
the 0.4 mg/kg dose of tenecteplase might lead to higher rates 
of intracerebral hemorrhage compared to the preferred 0.25 
mg/kg dose.7,14 Therefore, the trend towards less intracerebral 
hemorrhage would be more pronounced if patients who 
received tenecteplase at 0.4 mg/kg were excluded.
While stroke trials generally focus on intracerebral 
bleeding, it is worth considering the rates of other adverse 
bleeding events associated with the administration of alteplase 
and tenecteplase. There is an abundance of data from the 
cardiology literature comparing tenecteplase and alteplase 
with regards to adverse effects in patients with acute coronary 
syndrome. It is likely that the rates of adverse events other 
than intracerebral hemorrhage for tenecteplase and alteplase 
would be the same for patients with acute ischemic stroke as 
they would be for acute coronary syndrome. Thus, the relevant 
literature will be summarized below.
There are three randomized controlled trials that 
compared tenecteplase to alteplase for patients with acute 
coronary syndrome and reported the adverse effect of major 
bleeding (not just intracerebral hemorrhage).16-18 The largest of 
those trials was ASSENT-2, which randomly assigned patients 
with acute myocardial infarction to alteplase or tenecteplase.  
It found that patients who received tenecteplase had reduced 
rates of non-cerebral bleeding complications (26.43 vs 
28.95%, p=0.0003) and less need for blood transfusion (4.25 
vs 5.49%, p=0.0002). A meta-analysis that included that trial 
and the two other studies referenced above17-18 was completed, 
and included a total of 17,325 patients.19 It found a statistically 
significant reduction in major bleeding with tenecteplase as 
compared with alteplase (RR 0.79; 95% CI, 0.69-0.90; p= 
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0.0002). Another 2017 meta-analysis compared tenecteplase 
and alteplase along with streptokinase and reteplase for ST-
elevation myocardial infarction.20 It similarly found that 
tenecteplase use was associated with a lower risk of bleeding 
than other thrombolytic regimens.
In summary, no statistically significant difference has been 
reported in the available literature in the rates of intracerebral 
hemorrhage for tenecteplase versus alteplase in acute ischemic 
stroke patients. Moreover, the use of tenecteplase is associated 
with lower rates of non-cerebral bleeding than alteplase. 
Administration
As mentioned above, tenecteplase has greater fibrin 
specificity and a longer half-life than alteplase.5 These 
pharmacologic differences allow tenecteplase to be 
administered as a bolus, rather than a bolus followed by a 
drip (as with alteplase). While our nursing colleagues are 
certainly capable of preparing and administering alteplase, 
the dosing regimen of 0.09 mg/kg bolus followed by 0.81 mg/
kg as a drip over 60 minutes is a bit complicated. Perhaps this 
at least partially explains why there is data that pharmacist 
participation in acute ischemic stroke treatment is associated 
with decreased door-to-needle times.21 While many tertiary 
care facilities involve clinical pharmacists in stroke protocols, 
this is not feasible in rural hospitals, leaving the somewhat 
cumbersome task of preparing and administering alteplase 
entirely to nursing staff. 
Additionally, the administration of the alteplase drip 
requires an IV pump. Not all emergency medical technicians 
are qualified to manage IV pumps, which may, in certain 
circumstances, delay or complicate a patient’s interfacility 
transfer. The use of tenecteplase, which does not require 
a pump or any specialized equipment, would simplify the 
administration of thrombolytics and remove one potential 
barrier to rapid interfacility transfer for those stroke patients 
who require it.   
There is a great deal of emphasis on achieving rapid door-
to-needle times for thrombolytics in acute ischemic stroke.22 
However, what probably actually matters is not the door to 
thrombolytic initiation time, which is what is generally tracked 
as a quality measure, but rather the door to thrombolytic 
completion time. A patient who is given tenecteplase will have 
a one hour faster door to thrombolytic completion time than if 
they were given alteplase.  
Finally, when considering the administration of 
tenecteplase, it should be noted that the current evidence 
suggests that 0.25 mg/kg (maximum 25 mg) is the optimal 
dose. The 0.1 mg/kg dose did not fare as well as the 0.25 mg/
kg dose in the study by Parsons et al,8 and the 0.4 mg/kg dose 
may result in higher rates of intracerebral hemorrhage.7
Cost
Tenecteplase is consistently less expensive compared 
to alteplase nationally and internationally, with one study 
from Nepal stating that alteplase is twice as expensive 
as tenecteplase ($450 for tenecteplase versus $1000 for 
alteplase).23 According to drugs.com, in the United States, a 
50 mg vial of tenecteplase costs $6311.89, while a 100 mg 
vial of alteplase costs $9196.07.24 Given the doses of 0.25 
mg up to 25 mg for tenecteplase and 0.9 mg/kg up to 90 mg 
for alteplase, it is evident that tenecteplase costs much less. 
Moreover,  hospital prices may be much higher than those 
listed on drugs.com.  Thus, the switch from alteplase to 
tenecteplase has the potential to save hospitals and patients an 
enormous amount of money.
Conclusion
Tenecteplase is at least as effective as alteplase with 
regards to neurologic improvement after treatment of acute 
ischemic stroke.  Additionally, tenecteplase is less expensive, 
easier to administer, and may have less bleeding complications 
than alteplase.  Thus, physicians should consider using 
tenecteplase rather than alteplase for thrombolysis of acute 
ischemic stroke.  If used, the preferred dose of tenecteplase is 
0.25 mg/kg (maximum 25 mg).
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